Caricamento...
ABL regulation by AXL promotes cisplatin resistance in esophageal cancer
Esophageal adenocarcinoma (EAC) is characterized by resistance to chemotherapy and poor outcome. Although Cisplatin (CDDP) has been used as a first-line therapy in patients with EAC, resistance remains a major clinical problem. The AXL receptor tyrosine kinase, originally isolated as a transforming...
Salvato in:
| Pubblicato in: | Cancer Res |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2012
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5907497/ https://ncbi.nlm.nih.gov/pubmed/23117882 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-12-3151 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|